[{"address1": "2222 Ponce de Leon Boulevard", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786-629-1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 20, "auditRisk": 3, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 4, "overallRisk": 7, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 3.04, "open": 3.05, "dayLow": 3.0, "dayHigh": 3.072, "regularMarketPreviousClose": 3.04, "regularMarketOpen": 3.05, "regularMarketDayLow": 3.0, "regularMarketDayHigh": 3.072, "beta": 0.394, "forwardPE": -1.1744187, "volume": 78969, "regularMarketVolume": 78969, "averageVolume": 106406, "averageVolume10days": 72690, "averageDailyVolume10Day": 72690, "bid": 2.99, "ask": 3.05, "bidSize": 500, "askSize": 400, "marketCap": 91427824, "fiftyTwoWeekLow": 2.36, "fiftyTwoWeekHigh": 7.223, "fiftyDayAverage": 3.4996, "twoHundredDayAverage": 3.75215, "currency": "USD", "enterpriseValue": 7815127, "floatShares": 27749101, "sharesOutstanding": 30174200, "sharesShort": 1571257, "sharesShortPriorMonth": 1708145, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0521, "heldPercentInsiders": 0.080369994, "heldPercentInstitutions": 0.49355, "shortRatio": 15.78, "shortPercentOfFloat": 0.053000003, "impliedSharesOutstanding": 30274800, "bookValue": 2.388, "priceToBook": 1.2688442, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -94298296, "trailingEps": -3.13, "forwardEps": -2.58, "lastSplitFactor": "1:4", "lastSplitDate": 1569801600, "52WeekChange": 0.22672069, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RLMD", "underlyingSymbol": "RLMD", "shortName": "Relmada Therapeutics, Inc.", "longName": "Relmada Therapeutics, Inc.", "firstTradeDateEpochUtc": 1403271000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f101bc4b-2b97-3da3-a498-9e630b405138", "messageBoardId": "finmb_9070579", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.03, "targetHighPrice": 25.0, "targetLowPrice": 2.0, "targetMeanPrice": 10.63, "targetMedianPrice": 7.75, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 83612704, "totalCashPerShare": 2.771, "quickRatio": 6.764, "currentRatio": 6.825, "returnOnAssets": -0.55993, "returnOnEquity": -0.95484, "freeCashflow": -16231418, "operatingCashflow": -48190860, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]